Suchergebnisse - "Mellors, John W"

PubPharm (559)

71

In-Person Versus Tele-Infectious Disease (Tele-ID) Care : Is One Better?

enthalten in: Open forum infectious diseases | 2022

von Gupta, N. | Bariola, J. | Mellors, J. | +1

72

Potent and broad neutralization of SARS-CoV-2 variants of concern (VOCs) including omicron sub-lineages BA.1 and BA.2 by biparatopic human VH domains

enthalten in: iScience | 2022

von Chen, C. | Saville, J. | Marti, M. | +26

UpdateOf: bioRxiv. 2022 Feb 24;:. - PMID 35194603

73

SARS-CoV-2 variants of concern : spike protein mutational analysis and epitope for broad neutralization

enthalten in: Nature communications | 2022

von Mannar, D. | Saville, J. | Sun, Z. | +16

74

HIV infected CD4+ T cell clones are more stable than uninfected clones during long-term antiretroviral therapy

enthalten in: PLoS pathogens | 2022

von Guo, S. | Luke, B. | Henry, A. | +12

75

Deep Sequencing Analysis of Individual HIV-1 Proviruses Reveals Frequent Asymmetric Long Terminal Repeats

enthalten in: Journal of virology | 2022

von Joseph, K. | Halvas, E. | Brandt, L. | +7

76

Associations of HIV persistence, cigarette smoking, inflammation, and pulmonary dysfunction in people with HIV on antiretroviral therapy

enthalten in: Medicine | 2022

von Cyktor, J. | Qin, S. | Staines, B. | +10

77

How could HIV-1 drug resistance impact preexposure prophylaxis for HIV prevention?

enthalten in: Current opinion in HIV and AIDS | 2022

von Parikh, U. | Mellors, J.

78

Development of a Centralized Antimicrobial Stewardship Program Across a Diverse Health System and Early Antimicrobial Usage Trends

enthalten in: Open forum infectious diseases | 2022

von Khadem, T. | Nguyen, M. | Mellors, J. | +1

79

Associations Between Multiple Measures of HIV-1 Persistence in Persons on Suppressive Antiretroviral Therapy

enthalten in: The Journal of infectious diseases | 2022

von Bosch, R. | Gandhi, R. | Mar, H. | +4

80

Third-line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource-limited settings : ACTG A5288 strategy trial

enthalten in: Journal of the International AIDS Society | 2022

von Avihingsanon, A. | Hughes, M. | Salata, R. | +31